Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...

Health authorities in Zambia have halted a planned clinical trial for an HIV vaccine after the United States withdrew funding ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.